Recent advances in the development of mutation-specific KRAS inhibitors have renewed interest in understanding the impact of KRAS mutations across different malignancies, emphasizing the need for precise characterization of KRAS-driven tumor biology to guide targeted therapies [2,3]. This evidence concerns the gene KRAS and neoplasm.